Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis

Louis P. Gangarosa Sr., James M. Hill, Barry L. Thompson, Carol Leggett and J. Peter Rissing
The Journal of Infectious Diseases
Vol. 154, No. 6 (Dec., 1986), pp. 930-934
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30104975
Page Count: 5
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis
Preview not available

Abstract

The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20 to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P< .05). Ara-AMP significantly decreased the duration of shedding of virus (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

Page Thumbnails

  • Thumbnail: Page 
930
    930
  • Thumbnail: Page 
931
    931
  • Thumbnail: Page 
932
    932
  • Thumbnail: Page 
933
    933
  • Thumbnail: Page 
934
    934